MetaCap

Rhythm Pharmaceuticals Inc. (RYTM)

NASDAQ: RYTMHealth CareBiotechnology: Pharmaceutical PreparationsUSD

112.36-4.44 (-3.80%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

RYTM stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$2.91
52-week range
74.50 – 122.20
Day range
112.00 – 117.01
Volume / Avg
1.50M / 1.10M
Beta
—

52-week range

$74.50$122.20

RYTM stock today

Shares of Rhythm Pharmaceuticals (RYTM) finished lower on Nov 20 at $112.36, a drop of 3.80% or $4.44 per share, versus the S&P 500's 3.70% decline. At this level, RYTM sits in the middle of its 52-week range of $74.50 to $122.20: 8.1% below the high, set on Dec 11, 2025 and 50.8% above the low. RYTM is up 5.0% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 10.4%.

Rhythm Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$2.91), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Rhythm Pharmaceuticals

Company profile

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. David P. Meeker M.D.
Headquarters
Boston, MA
Employees
414
IPO year
2017

Financial highlights

Full financials

In fiscal 2025, Rhythm Pharmaceuticals generated $189.8 million in revenue, up 45.8% from fiscal 2024, its 5th consecutive year of revenue growth. Rhythm Pharmaceuticals reported a net loss of $196.5 million, compared with a loss of $260.6 million a year earlier. Gross margin was 89.7% (flat year over year) and operating margin -101.2%.

Rhythm Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$189.76M$130.13M$77.43M$23.64M$3.15M
Growth+45.83%+68.06%+227.56%+649.46%—
Net income$-196.54M$-260.60M$-184.68M$-181.12M$-69.61M
EPS (diluted)$-3.11$-4.34$-3.20$-3.47$-1.40

Analyst forecast

Forecast

Consensus (19 analysts)

strong_buy

Avg. price target

$140.12+24.71%

  • Strong buy 5
  • Buy 12
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $112.00High $168.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 3, 2026
EPS actual vs est.
$-0.61 vs $-0.68
Surprise
+10.29%

RYTM news

All RYTM news

Rhythm Pharmaceuticals peers

Health Care sector
RYTM peer companies
CompanyPrice% ChgMarket capCompare
PTGXProtagonist Therapeutics Inc.121.40-2.11%$7.92Bvs RYTM
SMMTSummit Therapeutics Inc.9.95-5.87%$7.96Bvs RYTM
ALKSAlkermes plc44.94-2.69%$7.55Bvs RYTM
KNSAKiniksa Pharmaceuticals International plc Class A93.90+0.38%$7.38Bvs RYTM
AMRXAmneal Pharmaceuticals Inc. Class A21.12-1.26%$7.36Bvs RYTM
PRAXPraxis Precision Medicines Inc.300.43-3.37%$8.40Bvs RYTM
CYTKCytokinetics Incorporated50.78-1.32%$7.07Bvs RYTM
CORTCorcept Therapeutics Incorporated63.62-2.09%$6.96Bvs RYTM

Indexes, lists and sector

Rhythm Pharmaceuticals stock FAQ

What is Rhythm Pharmaceuticals's stock price today?

RYTM last traded at $112.36 as of Nov 20, 4:00 PM EST, down 3.80% on the day. Prices are delayed at least 15 minutes.

Who is Rhythm Pharmaceuticals's CEO?

Dr. David P. Meeker M.D. is the chief executive officer of Rhythm Pharmaceuticals Inc., which has about 414 employees.

What is the RYTM 52-week high?

The 52-week high for RYTM is $122.20 and the 52-week low is $74.50. The stock is currently 8.1% below its high.

Compare RYTM